Compare Sunrun Inc (RUN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sunrun Inc vs TG Therapeutics Inc — how do they compare? Sunrun Inc trades at $7.54 (market cap $1.83B), while TG Therapeutics Inc trades at $54.84 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 4.5× Sunrun Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals.
| RUN | TGTX | |
|---|---|---|
Market Cap | $1.83B | $8.16B |
Volume | 8,672,852 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $21.41 | $59.06 |
52-Week Low | $7.59 | $26.94 |
Enterprise Value | $16.35B | $8.37B |
Typical Hold Time | — | 16 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sunrun (RUN) trades at $7.58, down 0.39% on the day, reflecting a bearish technical trend. The stock shows attractive valuation ratios with a P/E of 5.16 and P/S of 0.59, while recent quarterly earnings have consistently beaten expectations. However, cash flow from operations remains negative, and the company faces headwinds from high borrowing costs impacting the solar sector. Positive developments include a record 580 MW grid dispatch with Tesla and expanded partnerships for distributed computing.
The outlook is mixed: strong analyst support with a $16.33 price target suggests significant upside, but operational cash burn and sector volatility pose risks. Investors should weigh low valuations against execution challenges and macroeconomic pressures affecting solar financing.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
